All In Biotech

Free tool

FAERS Monitor: Urex

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 016151 or its brand name (Urex, Methenamine Hippurate). Reports on generic versions are filed under their own applications.

Reports

1,289

Serious

736

57% of reports

Hospitalization

353

Death reported

82

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • urinary tract infection169
  • diarrhoea83
  • drug ineffective83
  • nausea83
  • fatigue78
  • fall74
  • headache70
  • dizziness66
  • death57
  • product dose omission issue57
  • off label use52
  • pneumonia51
  • asthenia50
  • dyspnoea50
  • malaise47

Reports by year received

View as table
YearReports
20042
200510
20061
20071
20082
20091
20102
20115
201213
20139
201425
201552
201665
201758
201867
201972
202092
202191
202297
2023115
2024129
2025180
2026200

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,870 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
urinary tract infectionSignal16916.214.12,409
fallSignal743.62.9140
product dose omission issueSignal573.22.583
pneumoniaSignal512.62.048
astheniaSignal502.21.731
dizzinessSignal662.21.741
diarrhoeaSignal832.11.748
headache701.81.526
malaise471.71.315
nausea831.71.425
fatigue781.61.319
dyspnoea501.41.16
death571.10.80
drug ineffective831.00.80
off label use521.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.